Global Topical Drugs CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

List of Tables

The global demand for Topical Drugs CDMO Market is presumed to reach the market size of nearly USD 96.69 BN by 2030 from USD 37.58 BN in 2022 with a CAGR of 12.54% under the study period 2023 - 2030.

Topical drugs CDMO refers to companies or organizations that provide Contract Development and Manufacturing Outsourcing services specifically for topical pharmaceutical drugs. CDMO stands for Contract Development and Manufacturing Organization, and these entities specialize in supporting the pharmaceutical and biotechnology industries by offering services related to the development, manufacturing, and sometimes commercialization of drugs.

MARKET DYNAMICS:

The Topical Drugs Contract Development and Manufacturing Organization (CDMO) market is thriving due to several key factors. The increasing complexity of drug development, particularly in the formulation design for topical drugs, propels pharmaceutical companies to leverage the specialized expertise of CDMOs. Cost efficiency is a significant driver, as outsourcing to Topical drugs CDMOs provides access to specialized services and infrastructure without substantial in-house investments. The focus on core competencies allows pharmaceutical companies to concentrate on research and marketing while relying on CDMOs for the development and manufacturing of topical drugs. The rising demand for topical drug products, advancements in formulation technologies, and the imperative of regulatory compliance further contribute to the growth of this market. Globalization, flexibility, scalability, and the trend of outsourcing in the pharmaceutical industry underscore the pivotal role of Topical drugs CDMOs in accelerating drug development timelines and meeting market demands efficiently. As pharmaceutical companies seek strategic partnerships to navigate the evolving landscape, Topical drugs CDMOs emerge as crucial collaborators in the pharmaceutical supply chain.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of topical drugs cdmo. The growth and trends of topical drugs cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the topical drugs cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

Semi-Solid Formulations (Creams, Ointments, Gel, Others)
Liquid Formulations Drugs
Solid Formulations
Transdermal Products

By Service Type

Contract Development
Contract Manufacturing

By End-Use

Pharmaceutical Companies
Biopharmaceutical Companies
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Topical Drugs CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Topical Drugs CDMO market include Lubrizol Life Science, Cambrex Corporation, Contract Pharmaceuticals Limited, Bora Pharmaceutical CDMO, Ascendia Pharmaceuticals, Pierre Fabre group, Piramal Pharma Solutions, DPT Laboratories, LTD., MedPharm Ltd., PCI Pharma Services. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112112775

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . TOPICAL DRUGS CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product Type
- 3.7.2 Market Attractiveness Analysis By Service Type
- 3.7.3 Market Attractiveness Analysis By End-use
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL TOPICAL DRUGS CDMO MARKET ANALYSIS BY PRODUCT TYPE

5.1 Overview by Product Type
5.2 Historical and Forecast Data
5.3 Analysis by Product Type
5.4 Semi-solid Formulations (Creams, Ointments, Gel, Others) Historic and Forecast Sales by Regions
5.5 Liquid Formulations Drugs Historic and Forecast Sales by Regions
5.6 Solid Formulations Historic and Forecast Sales by Regions
5.7 Transdermal Products Historic and Forecast Sales by Regions

6 . GLOBAL TOPICAL DRUGS CDMO MARKET ANALYSIS BY SERVICE TYPE

6.1 Overview by Service Type
6.2 Historical and Forecast Data
6.3 Analysis by Service Type
6.4 Contract Development Historic and Forecast Sales by Regions
6.5 Contract Manufacturing Historic and Forecast Sales by Regions

7 . GLOBAL TOPICAL DRUGS CDMO MARKET ANALYSIS BY END-USE

7.1 Overview by End-use
7.2 Historical and Forecast Data
7.3 Analysis by End-use
7.4 Pharmaceutical Companies Historic and Forecast Sales by Regions
7.5 Biopharmaceutical Companies Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL TOPICAL DRUGS CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE TOPICAL DRUGS CDMO COMPANIES

9.1. Topical Drugs Cdmo Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF TOPICAL DRUGS CDMO INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Lubrizol Life Science
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Cambrex Corporation
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Contract Pharmaceuticals Limited
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Bora Pharmaceutical CDMO
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Ascendia Pharmaceuticals
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Pierre Fabre group
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Piramal Pharma Solutions
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. DPT Laboratories LTD.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. MedPharm Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. PCI Pharma Services
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies